Guest guest Posted July 28, 2008 Report Share Posted July 28, 2008 The Prostate Cancer Prevention Trial (PCPT) has challenged the validity of recommended prostate-specific antigen (PSA) thresholds for prostate biopsy (>2.5ng/ml) given the 17% prostate cancer (pCA) detection rate at PSA of 1.1-2.0. The outcome of patients treated at PSA < /=2.5 is poorly defined, and advantages associated with such an early diagnosis are uncertain.Click on the below link for the full story:<http://www.urotoday.com/61/browse_categories/prostate_cancer/analysis_of_t1c_prostate_cancers_treated_at_very_low_prostatespecific_antigen_levels__abstract.html> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.